Last reviewed · How we verify
Vonoprazan 20 mg
Vonoprazan 20 mg is a Small molecule drug developed by Rehman Medical Institute - RMI. It is currently FDA-approved. Also known as: Potassium-competitive acid blocker, TAK-438, Takecab, vocinti.
Vonoprazan 20 mg, marketed by Rehman Medical Institute (RMI), is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a significant competitive advantage due to its patent protection until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Vonoprazan 20 mg |
|---|---|
| Also known as | Potassium-competitive acid blocker, TAK-438, Takecab, vocinti |
| Sponsor | Rehman Medical Institute - RMI |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (NA)
- Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. (NA)
- Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication (NA)
- Vonoprazan Test for PPI Refractory GERD (NA)
- A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks (PHASE2)
- Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication (PHASE3)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonoprazan 20 mg CI brief — competitive landscape report
- Vonoprazan 20 mg updates RSS · CI watch RSS
- Rehman Medical Institute - RMI portfolio CI
Frequently asked questions about Vonoprazan 20 mg
What is Vonoprazan 20 mg?
Who makes Vonoprazan 20 mg?
Is Vonoprazan 20 mg also known as anything else?
What development phase is Vonoprazan 20 mg in?
Related
- Manufacturer: Rehman Medical Institute - RMI — full pipeline
- Also known as: Potassium-competitive acid blocker, TAK-438, Takecab, vocinti
- Compare: Vonoprazan 20 mg vs similar drugs
- Pricing: Vonoprazan 20 mg cost, discount & access